| scholarly article | Q13442814 |
| P2093 | author name string | Jing Yu | |
| Heng Li | |||
| Li Zhuang | |||
| Xudong Xiang | |||
| Huicheng Chen | |||
| Gaofeng Li | |||
| Xiumei Yang | |||
| P2860 | cites work | Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Q24600932 |
| MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma | Q24653676 | ||
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| The PTEN tumor suppressor gene and its role in lymphoma pathogenesis | Q26776527 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation | Q27852528 | ||
| Analyzing real-time PCR data by the comparative C(T) method | Q28131831 | ||
| PTEN: life as a tumor suppressor | Q28203431 | ||
| MicroRNA signatures in human ovarian cancer | Q28249211 | ||
| The quest to overcome resistance to EGFR-targeted therapies in cancer | Q33725976 | ||
| Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells | Q33921596 | ||
| A systematic review of the impact of stigma and nihilism on lung cancer outcomes | Q34274235 | ||
| Is previous respiratory disease a risk factor for lung cancer? | Q34425781 | ||
| Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas | Q34531091 | ||
| Evaluation of the impact of the cancer therapy everolimus on the central nervous system in mice | Q34600979 | ||
| 18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice | Q35120054 | ||
| Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma | Q35677757 | ||
| Identification of Differentially Expressed miRNAs in Appendiceal Mucinous Cystadenocarcinoma from Mucinous Cystadenoma | Q36483432 | ||
| Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase | Q37223362 | ||
| Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment | Q37572922 | ||
| Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors. | Q37703384 | ||
| Regulation of immune responses by mTOR. | Q37963950 | ||
| ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. | Q38686925 | ||
| The enhanced tumor inhibitory effects of gefitinib and L-ascorbic acid combination therapy in non-small cell lung cancer cells | Q38697702 | ||
| Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. | Q38833458 | ||
| Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer | Q38876622 | ||
| Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma | Q39396713 | ||
| Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer | Q40017234 | ||
| Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. | Q40101428 | ||
| Integrated miRNA and mRNA expression profiling of tension force-induced bone formation in periodontal ligament cells. | Q40819642 | ||
| Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial | Q42699372 | ||
| miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. | Q45944020 | ||
| mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor | Q46119164 | ||
| miR-205 regulates the proliferation and invasion of ovarian cancer cells via suppressing PTEN/SMAD4 expression. | Q54090230 | ||
| Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells. | Q54112994 | ||
| MicroRNA-92a promotes tumor growth and suppresses immune function through activation of MAPK/ERK signaling pathway by inhibiting PTEN in mice bearing U14 cervical cancer. | Q54213961 | ||
| Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. | Q54979178 | ||
| Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer. | Q55210260 | ||
| Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update | Q57102017 | ||
| Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer | Q57106666 | ||
| PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent Manner | Q57591077 | ||
| A mono-carbonyl analog of curcumin induces apoptosis in drug-resistant EGFR-mutant lung cancer through the generation of oxidative stress and mitochondrial dysfunction | Q58693828 | ||
| Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway | Q58804958 | ||
| Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas | Q74418921 | ||
| Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast | Q80379623 | ||
| PTEN: Tumor Suppressor and Metabolic Regulator | Q90429880 | ||
| Cancer statistics, 2019 | Q90941571 | ||
| Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN | Q91771567 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 5 | |
| P304 | page(s) | 5269-5276 | |
| P577 | publication date | 2019-09-19 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Everolimus inhibits the proliferation and migration of epidermal growth factor receptor-resistant lung cancer cells A549 via regulating the microRNA-4328/phosphatase and tensin homolog signaling pathway | |
| P478 | volume | 18 |
| Q96953242 | Flaming the fight against cancer cells: the role of microRNA-93 | cites work | P2860 |
Search more.